EFFECTIVENESS OF PET/CT IN EVALUATION OF THE LYMPHOMA

Year 2019, Volume: 6 Issue: 3, 75 - 79, 30.10.2019

Göktuğ Atnallar Büşra Özdemir Elif Gülsüm Ümit Gülay Durmuş Altun

Abstract

1. Aims: Prognosis and survival of Hodgkin lymphoma have been improved dramatically by the development of treatments as well as the sensitivity of evaluation tools. In this case report, we aimed to emphasize the importance of positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography in the initial staging of Hodgkin’s lymp-homa, evaluating the response to treatment, and to demonstrate residual tissue or recurrence. Case Report: A 25-year-old male patient presented to Trakya University Hospital with swelling in the right groin and was diagnosed with Hodgkin’s lymphoma. Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography scan was used for initial staging and assessment of response to treatment. Conclusion: Positron emission tomography is a feasible imaging modality for the evaluation of lymphomas. It is sensitive to detect minimal recurrence as well as alterations of lesions’ metabolic activity. Keywords: Positron emission tomography, lymphoma, hodgkin disease

Keywords

Positron emission tomography, lymphoma, , hodgkin disease

References

• 1. Vinay K, Abbas AK, Jon C. Robbins Temel Patoloji. In: Sıtkı T, Mine G, Uğur Ç. 9.Basım. İstanbul: Nobel Tıp Kitabevi; 2013.p.440-4.
• 2. Turkish Hematology Association. Hodgkin lymphoma diagnosis and treatment guide. (cited 2019 June 3). Available from: URL:ht-tp://www.thd.org.tr/thdData/userfiles/file/hodgkin_lenfoma_teda-vi_rehberi.pdf.
• 3. Sanem ŞM, Metin H, Kerim S et al. Importance of the imaging pro-tocol of FDG PET/CT in lymphomas. Turk J Nucl Med 2007;16:69-72.
• 4. Gobbi PG, Ghirardelli ML, Solcia M et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognos-tic importance. J Clin Oncol 2001;19(5):1388-94.
• 5. Barrington S, Kluge R. FDG PET for therapy monitoring in Ho-dgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 2017;44(1):97–110.
• 6. Moog F, Bangerter M, Diederichs CG et al. Extranodal malig-nant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81.
• 7. Sasaki M, Kuwabara Y, Koga H et al. Clinical impact of whole-body FDG-PET on the staging and therapeutic decision making for malig-nant lymphoma. Ann Nucl Med 2002;16:337-45.
• 8. Kurt M, Çetintaş S, Öztürk A. The role of positron emission to-mography (PET) use in hodgkin lymphoma follow-up. Uludağ Üni-versitesi Tıp Fakültesi Dergisi 2007;33:51-4.
• 9. Subocz E, Halka J, Dziuk M. The role of FDG-PET in Hodgkin lymphoma. Contemp Oncol (Pozn) 2017;21(2):104-14.
• 10. İlknur A. Lenfomaların takip ve tedavisinde F-18 FDG PET’in yeri. Türk Hematoloji Derneği (online) 2006 May. Available from: URL:http://www.thd.org.tr/thdData/userfiles/file/14_05_2006_ilk-nur_ak_12-55_13-15.pdf January 2019.
• 11. Cheson BD, Pfistner B et al. Revised response criteria for malig-nant lymphoma. J Clin Oncol 2007;25(5):579-86.